Research ExplorerPublicationsClinical application of circulating tumor cells in breast ca...

Clinical application of circulating tumor cells in breast cancer: overview of the current interventional trials.

Standard

Clinical application of circulating tumor cells in breast cancer: overview of the current interventional trials. / Bidard, François-Clément; Fehm, Tanja; Ignatiadis, Michail; Smerage, Jeffrey B; Alix-Panabières, Catherine; Janni, Wolfgang; Messina, Carlo; Paoletti, Costanza; Müller, Volkmar; Hayes, Daniel F; Piccart, Martine; Pierga, Jean-Yves.

In: CANCER METAST REV, Vol. 32, No. 1-2, 1-2, 2013, p. 179-188.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Bidard, F-C, Fehm, T, Ignatiadis, M, Smerage, JB, Alix-Panabières, C, Janni, W, Messina, C, Paoletti, C, Müller, V, Hayes, DF, Piccart, M & Pierga, J-Y 2013, 'Clinical application of circulating tumor cells in breast cancer: overview of the current interventional trials.', CANCER METAST REV, vol. 32, no. 1-2, 1-2, pp. 179-188. <http://www.ncbi.nlm.nih.gov/pubmed/23129208?dopt=Citation>

APA

Bidard, F-C., Fehm, T., Ignatiadis, M., Smerage, J. B., Alix-Panabières, C., Janni, W., Messina, C., Paoletti, C., Müller, V., Hayes, D. F., Piccart, M., & Pierga, J-Y. (2013). Clinical application of circulating tumor cells in breast cancer: overview of the current interventional trials. CANCER METAST REV, 32(1-2), 179-188. [1-2]. http://www.ncbi.nlm.nih.gov/pubmed/23129208?dopt=Citation

Vancouver

Bidard F-C, Fehm T, Ignatiadis M, Smerage JB, Alix-Panabières C, Janni W et al. Clinical application of circulating tumor cells in breast cancer: overview of the current interventional trials. CANCER METAST REV. 2013;32(1-2):179-188. 1-2.

Bibtex

@article{382aef1ae7ad41c6accf278813eb88ff,
title = "Clinical application of circulating tumor cells in breast cancer: overview of the current interventional trials.",
abstract = "In 2004, circulating tumor cells (CTC) enumeration by the CellSearch{\textregistered} technique at baseline and during treatment was reported to be associated with prognosis in metastatic breast cancer patients. In 2008, the first evidence of the impact of CTC detection by this technique on survival of cM0(i+) patients were reported. These findings were confirmed by other non-interventional studies, whereas CTC were also investigated as a surrogate for tumor biology, mainly for HER2 expression/amplification. The aim of this report is to present the current prospective large interventional studies that have been specifically designed to demonstrate that CTC enumeration/characterization may improve the management of breast cancer patients: STIC CTC METABREAST (France) and Endocrine Therapy Index (USA) assess the CTC-guided hormone therapy vs chemotherapy decision in M1 patients; SWOG0500 (USA) and CirCe01 (France) assess the CTC count changes during treatment in metastatic patients; DETECT III (M1 patients, Germany) and Treat CTC (cM0(i+) patients, European Organization for Research and Treatment of Cancer/Breast International Group) assess the use of anti-HER2 treatments in HER2-negative breast cancer patients selected on the basis of CTC detection/characterization. These trials have different designs in various patient populations but are expected to be the pivotal trials for CTC implementation in the routine management of breast cancer patients.",
author = "Fran{\c c}ois-Cl{\'e}ment Bidard and Tanja Fehm and Michail Ignatiadis and Smerage, {Jeffrey B} and Catherine Alix-Panabi{\`e}res and Wolfgang Janni and Carlo Messina and Costanza Paoletti and Volkmar M{\"u}ller and Hayes, {Daniel F} and Martine Piccart and Jean-Yves Pierga",
year = "2013",
language = "English",
volume = "32",
pages = "179--188",
journal = "CANCER METAST REV",
issn = "0167-7659",
publisher = "Springer Netherlands",
number = "1-2",

}

RIS

TY - JOUR

T1 - Clinical application of circulating tumor cells in breast cancer: overview of the current interventional trials.

AU - Bidard, François-Clément

AU - Fehm, Tanja

AU - Ignatiadis, Michail

AU - Smerage, Jeffrey B

AU - Alix-Panabières, Catherine

AU - Janni, Wolfgang

AU - Messina, Carlo

AU - Paoletti, Costanza

AU - Müller, Volkmar

AU - Hayes, Daniel F

AU - Piccart, Martine

AU - Pierga, Jean-Yves

PY - 2013

Y1 - 2013

N2 - In 2004, circulating tumor cells (CTC) enumeration by the CellSearch® technique at baseline and during treatment was reported to be associated with prognosis in metastatic breast cancer patients. In 2008, the first evidence of the impact of CTC detection by this technique on survival of cM0(i+) patients were reported. These findings were confirmed by other non-interventional studies, whereas CTC were also investigated as a surrogate for tumor biology, mainly for HER2 expression/amplification. The aim of this report is to present the current prospective large interventional studies that have been specifically designed to demonstrate that CTC enumeration/characterization may improve the management of breast cancer patients: STIC CTC METABREAST (France) and Endocrine Therapy Index (USA) assess the CTC-guided hormone therapy vs chemotherapy decision in M1 patients; SWOG0500 (USA) and CirCe01 (France) assess the CTC count changes during treatment in metastatic patients; DETECT III (M1 patients, Germany) and Treat CTC (cM0(i+) patients, European Organization for Research and Treatment of Cancer/Breast International Group) assess the use of anti-HER2 treatments in HER2-negative breast cancer patients selected on the basis of CTC detection/characterization. These trials have different designs in various patient populations but are expected to be the pivotal trials for CTC implementation in the routine management of breast cancer patients.

AB - In 2004, circulating tumor cells (CTC) enumeration by the CellSearch® technique at baseline and during treatment was reported to be associated with prognosis in metastatic breast cancer patients. In 2008, the first evidence of the impact of CTC detection by this technique on survival of cM0(i+) patients were reported. These findings were confirmed by other non-interventional studies, whereas CTC were also investigated as a surrogate for tumor biology, mainly for HER2 expression/amplification. The aim of this report is to present the current prospective large interventional studies that have been specifically designed to demonstrate that CTC enumeration/characterization may improve the management of breast cancer patients: STIC CTC METABREAST (France) and Endocrine Therapy Index (USA) assess the CTC-guided hormone therapy vs chemotherapy decision in M1 patients; SWOG0500 (USA) and CirCe01 (France) assess the CTC count changes during treatment in metastatic patients; DETECT III (M1 patients, Germany) and Treat CTC (cM0(i+) patients, European Organization for Research and Treatment of Cancer/Breast International Group) assess the use of anti-HER2 treatments in HER2-negative breast cancer patients selected on the basis of CTC detection/characterization. These trials have different designs in various patient populations but are expected to be the pivotal trials for CTC implementation in the routine management of breast cancer patients.

M3 - SCORING: Journal article

VL - 32

SP - 179

EP - 188

JO - CANCER METAST REV

JF - CANCER METAST REV

SN - 0167-7659

IS - 1-2

M1 - 1-2

ER -